Preoperative monocyte-to-lymphocyte ratio as a potential predictor of bladder cancer

J Basic Clin Physiol Pharmacol. 2022 Aug 22;33(6):751-757. doi: 10.1515/jbcpp-2022-0179. eCollection 2022 Nov 1.

Abstract

Objectives: The aim of this study was to investigate the role of preoperative Monocyte-to-Lymphocyte ratio (MLR) as a potential predictor of bladder cancer (BC).

Methods: Clinical data of patients who underwent TURBT at our institution between 2017 and 2021 were collected and retrospectively analysed. MLR was obtained from preoperative blood analyses performed within 1 month from hospital admission. The association of MLR with different clinic-pathological features obtained from histological reports was further analysed. Statistical analysis was performed using the Kruskal Wallis test for non-parametric variables, assuming p<0.05 as statistically significant.

Results: 510 patients were included in the study (81% males, 19% females), with a mean age of 71.66 ± 11.64 years. Mean MLR was higher in patients with any-type bladder cancer, reporting an MLR of 0.41 ± 0.11 compared to 0.38 ± 0.43 in patients without bladder cancer (p=0.043). In the subsequent comparison among low-grade and high-grade bladder cancer, MLR did not report statistically significant differences, with 0.29 ± 0.12 for low-grade BC and 0.51 ± 0.81 for high-grade BC (p=0.085).

Conclusions: Our findings reported elevated preoperative MLR should be considered a potential biomarker predicting malignancy for bladder tumours. Furthermore, research are necessary to assess its role in discerning low-grade from high-grade patients.

Keywords: inflammation biomarkers; monocyte; monocyte-to-lymphocyte ratio; non muscle invasive bladder cancer.

MeSH terms

  • Aged
  • Aged, 80 and over
  • Female
  • Humans
  • Lymphocytes
  • Male
  • Middle Aged
  • Monocytes* / pathology
  • Neutrophils
  • Prognosis
  • Retrospective Studies
  • Urinary Bladder Neoplasms* / diagnosis
  • Urinary Bladder Neoplasms* / pathology